90 Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies
Open Access
- 1 September 2015
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 51 (14) , 1857-1864
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 TrialJournal of Clinical Oncology, 2014
- NAPOLI-1: Randomized Phase 3 Study of MM-398 (NAL-IRI), with or Without 5-Fluorouracil and Leucovorin, Versus 5-Fluorouracil and Leucovorin, in Metastatic Pancreatic Cancer Progressed on or Following Gemcitabine-Based TherapyAnnals of Oncology, 2014
- Transport properties of pancreatic cancer describe gemcitabine delivery and responseJournal of Clinical Investigation, 2014
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trialsAnnals of Oncology, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Pancreatic CancerNew England Journal of Medicine, 2010
- Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2007
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucinInternational Journal of Cancer, 1994